Effects of Krill Oil on Human Health
Conditions
Keywords
Dietary restriction, oxidative stress, fasting
Brief summary
The investigators hypothesized that individuals supplementing with krill oil capsules (two grams per day) would experience enhanced improvements in health-related variables during a 21-day Daniel Fast.
Detailed description
One of the main purposes of the this investigation was to determine if krill oil supplementation (two grams per day for 21 days) enhances the effects of a 21-day Daniel Fast, particularly in regards to blood lipids and lipid peroxidation. The investigators were also interested in determining if adiponectin and/or resistin change in response to the fast, as these adipokines could potentially mediate the favorable glucoregulatory changes the investigators observed in our initial investigation of a 21-day Daniel Fast. Finally, the investigators sought to determine the changes in macronutrient and micronutrient intake during a Daniel Fast, and how these dietary changes affect our selected hemodynamic, anthropometric, blood lipid, glucoregulatory, oxidative stress, inflammatory, renal, and hepatic biomarkers.
Interventions
DIETARY_SUPPLEMENTKrill oil supplementation
During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
Sponsors
University of Memphis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Must be 18 years of age or older. * Must be willing to partake in a vegan diet for 21 days. * Must be willing to consume either krill oil or coconut oil capsules (assigned randomly).
Exclusion criteria
* Smokers * regular consumption of antioxidant supplements * women who were pregnant or seeking to become pregnant * poor veins (veins that made it difficult to successfully obtain a blood draw - this was determined via a visual inspection)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| C-reactive protein | Change from baseline at 3 weeks | — |
| Glucoregulatory markers | Change from baseline at 3 weeks | Blood glucose, blood insulin, Serum resistin, serum adiponectin |
| Markers of Oxidative Stress and Antioxidant Status | Change from baseline at 3 weeks | Plasma malondialdehyde, plasma hydrogen peroxide, plasma nitrate/nitrite, Trolox Equivalent Antioxidant Capacity (measured in serum) |
| Blood Pressure | Change from baseline at 3 weeks | Systolic blood pressure, diastolic blood pressure |
| Blood Lipids | Change from baseline at 3 weeks | Total Cholesterol, LDL-C, HDL-C, VLDL-C, Triglyerides |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic Panel | Change from baseline at 3 weeks | Blood urea nitrogen, creatinine, sodium, potassium, carbon dioxide, calcium, protein, albumin, globulin, bilirubin, alkaline phosphatase, aspartate transaminase, alanine transaminase |
| Complete Blood Count | Change from baseline at 3 weeks | White blood cells, red blood cells, hemoglobin, hematocrit, mean cell volume, mean cell hemoglobin, mean corpuscular hemoglobin concentration, red blood cell distribution width, platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils |
| Anthropometric Variables | Change from baseline at 3 weeks | bodyweight, body mass index, waist circumference, hip circumference, body fat percentage, fat mass, fat free mass |
Countries
United States
Outcome results
None listed